Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT07422857 | Recruiting Phase 3

• 1 other identifier: DCAMS-F10-302
• Study Type: interventional
• Target: 316
• Locations: 1 country
• Sites: 2

Brief Summary

This study is to evaluate the efficacy and safety of \[18F\]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.

Conditions

Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

Outcome Measures

Primary Outcomes (1)

• Evaluate the effectiveness of visual reading results of [18 F]-APN-1607 injection PET imaging in detecting tau NFTs（Neurofibrillary Tangles）

  Sensitivity and specificity of PET imaging visual interpretation results of \[ 18 F\]-APN-1607 injection compared with true standards

  15 months

Secondary Outcomes (2)

• Assessment of [18 F]-APN-1607 Uptake Patterns by Regional SUVR Values and the capability in differentiating different groups

  15 months

• Safety and Tolerability Profile Measured by Adverse Events (AEs)

  15 months

Study Arms (3)

Alzheimer's Disease

EXPERIMENTAL

AD subjects will undergo PET imaging using \[18F\]APN-1607.

Drug: [18F]-APN-1607

Mild Cognitive Impairment Due to Alzheimer's Disease

EXPERIMENTAL

MCI subjects will undergo PET imaging using \[18F\]APN-1607.

Drug: [18F]-APN-1607

Healthy Volunteers

OTHER

Healthy control subjects will undergo PET imaging using \[18F\]APN-1607.

Drug: [18F]-APN-1607

Interventions

[18F]-APN-1607 DRUG

Participants will receive a single intravenous injection of 5-7 mCi of \[18F\]-APN-1607, and a whole-body PET/CT scan will begin immediately after administration.

Alzheimer's Disease; Healthy Volunteers; Mild Cognitive Impairment Due to Alzheimer's Disease

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be able to understand and voluntarily sign a written informed consent form (ICF);
• Age ≥ 50 years, regardless of gender;
• Subjects with HV, MCI, and AD should meet the clinical diagnostic criteria
• Can tolerate brain MRI and PET imaging examinations;
• For women of potential fertility (not yet menopausal or within 2 years of menopause), effective contraception must be used during the study and for 3 months after the study (effective contraception refers to sterilization, intrauterine hormonal devices, condoms, birth control pills, abstinence, or partner vasectomy, etc.); male participants should agree to use contraception during the study and for 3 months after the study.

You may not qualify if:

• Specific clinical phenotypes of atypical AD as defined in the 2014 IWG-2 criteria
• Possible presence of frontotemporal degeneration (FTLD), characterized by progressive psych behavioral abnormalities and executive dysfunction，Characterized primarily by impairment and language function, progressive aphasia
• The core symptoms of Lewy body dementia include fluctuating cognitive changes accompanied by significant attention and arousal abnormalities, recurrent typical visual hallucinations, and spontaneous symptoms of Parkinson's syndrome;
• Currently suffering from significant mental illness. Subjects with accompanying psychiatric symptoms need to be carefully evaluated by the researchers to determine whether they can complete the imaging process;
• Brain structural abnormalities confirmed by MRI, such as large strokes (infarct area greater than 4 cm) or intracranial space-occupying lesions;
• Suffering from claustrophobia or unable to tolerate imaging procedures for other reasons;
• History of alcohol or drug abuse/dependency;
• Hypersensitivity to the investigational drug or any of its components;
• Currently pregnant or breastfeeding;
• Received non-vaccine investigational treatment for Alzheimer's disease or other dementia within 3 months prior to screening, or received passive immunotherapy (antibody) for the treatment of Alzheimer's disease or other dementia within 6 months prior to screening, or previously received a vaccine for the treatment of Alzheimer's disease or other dementia; or participated in other new drug clinical trials within 30 days prior to enrollment;
• At present, the researcher suffers from serious diseases, such as infectious diseases, infectious diseases, endocrine or metabolic diseases, as well as serious cardiac function, liver function, lung function, and kidney function damage, and believes that participation in this study will have adverse effects on the subject or the research results
• Currently suffering from a disease or factor that causes QT interval prolongation, including torsades de pointes, QT prolongation syndrome, hyperkalemia, hypocalcemia, or taking medications that can prolong the QT interval, such as quinidine, amiodarone, or sotalol
• There are other situations that researchers consider unsuitable for participating in the experiment.

Sponsors & Collaborators

• JYAMS PET Research & Development Limited: lead

Study Sites (2)

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

NOT YET RECRUITING

Huashan Hospital of Fudan University

Shanghai, Province, 201199, China

RECRUITING

MeSH Terms

Conditions

Alzheimer Disease; Dementia

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2026
• First Posted: February 20, 2026
• Study Start: January 22, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): February 1, 2027
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)